These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
443 related articles for article (PubMed ID: 29611447)
1. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Avery LM; Nicolau DP Expert Opin Investig Drugs; 2018 Apr; 27(4):325-338. PubMed ID: 29611447 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Giacobbe DR; Mikulska M; Viscoli C Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1219-1236. PubMed ID: 30444147 [TBL] [Abstract][Full Text] [Related]
3. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Karaiskos I; Galani I; Souli M; Giamarellou H Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244 [TBL] [Abstract][Full Text] [Related]
5. Variation in definitions and isolation procedures for multidrug-resistant Gram-negative bacteria: a survey of the Society for Healthcare Epidemiology of America Research Network. Drees M; Pineles L; Harris AD; Morgan DJ Infect Control Hosp Epidemiol; 2014 Apr; 35(4):362-6. PubMed ID: 24602940 [TBL] [Abstract][Full Text] [Related]
6. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Jabbour JF; Sharara SL; Kanj SS Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742 [TBL] [Abstract][Full Text] [Related]
7. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. Hawkey PM; Warren RE; Livermore DM; McNulty CAM; Enoch DA; Otter JA; Wilson APR J Antimicrob Chemother; 2018 Mar; 73(suppl_3):iii2-iii78. PubMed ID: 29514274 [TBL] [Abstract][Full Text] [Related]
8. Collateral benefit of screening patients for methicillin-resistant Staphylococcus aureus at hospital admission: isolation of patients with multidrug-resistant gram-negative bacteria. Jones M; Nielson C; Gupta K; Khader K; Evans M Am J Infect Control; 2015 Jan; 43(1):31-4. PubMed ID: 25442394 [TBL] [Abstract][Full Text] [Related]
9. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations. Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276 [TBL] [Abstract][Full Text] [Related]
10. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Giamarellou H Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924 [TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. ; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340 [TBL] [Abstract][Full Text] [Related]
12. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Falcone M; Paterson D J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599 [TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Karaiskos I; Giamarellou H Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095 [TBL] [Abstract][Full Text] [Related]
14. ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery. Righi E; Mutters NT; Guirao X; Del Toro MD; Eckmann C; Friedrich AW; Giannella M; Kluytmans J; Presterl E; Christaki E; Cross ELA; Visentin A; Sganga G; Tsioutis C; Tacconelli E Clin Microbiol Infect; 2023 Apr; 29(4):463-479. PubMed ID: 36566836 [TBL] [Abstract][Full Text] [Related]
15. Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat? Sarda C; Fazal F; Rello J Expert Rev Respir Med; 2019 Aug; 13(8):787-798. PubMed ID: 31210549 [No Abstract] [Full Text] [Related]
16. Fight Against Antimicrobial Resistance: We Always Need New Antibacterials but for Right Bacteria. Duval RE; Grare M; Demoré B Molecules; 2019 Aug; 24(17):. PubMed ID: 31470632 [TBL] [Abstract][Full Text] [Related]
17. The role of fosfomycin for multidrug-resistant gram-negative infections. Bassetti M; Graziano E; Berruti M; Giacobbe DR Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411 [TBL] [Abstract][Full Text] [Related]
18. Bacterial profile, and independent predictors for healthcare-associated pneumonia persistently caused by multidrug-resistant Gram-negative bacteria for patients with the preceding multidrug-resistant Gram-negative pneumonia in Taiwan. Kuo LK; Chang HT; Hsueh SC; Liu IM; Hsieh PC; Jean SS J Microbiol Immunol Infect; 2024 Oct; 57(5):801-811. PubMed ID: 39147627 [TBL] [Abstract][Full Text] [Related]
19. The role of carbapenem-resistant pathogens in cSSTI and how to manage them. Del Giacomo P; Losito AR; Tumbarello M Curr Opin Infect Dis; 2019 Apr; 32(2):113-122. PubMed ID: 30648994 [TBL] [Abstract][Full Text] [Related]